Other

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Societe Valbiofrance

Therapeutiques Substitutives

Organes Tissus Regeneration Reparation Replacement—otr3

Valbiofrance

Organes Tissus Regeneration Reparation Remplacement - Otr3

Denis S Barritault

Jean-Pierre Caruelle

Jose P Courty

Yves Courtois

Michel Prunieras

Jean Gautron

Anne Meddahi

Isabelle Guedon Born Saglier

Cristina Arruti

Jacqueline Jozefonvicz

José Courty

Jacqueline Jozefonvicz Nee Dorgebray

Ammar Achour

Ahmed Aamiri

Faouzi Slaoui

Michele Tardieu

Isabelle Pierrot

Pascal Desgranges

Jean Delbe

Khalid Laaroubi

Yves Pouliquen

Pierre Milhiet

Josette Badet Nee Genissel

Veronique Barbier-Chassefiere

Marie-Anne Dourges Nee Jacquot

Danielle Gulino Nee Debrac

Some embodiments are directed to a pharmaceutical composition including a biocompatible polymer in association with a eukaryotic cell, a platelet extract and/or lysate, or a growth factor, to be used as a drug for the prevention and/or treatment of tissue lesions. Some other embodiments are also directed to a pharmaceutical kit which includes a biocompatible polymer in association with a eukaryotic cell for the prevention and/or treatment of tissue lesions. Some other embodiments are also directed to the use of a pharmaceutical composition including a biocompatible polymer in association with a eukaryotic cell, a platelet extract and/or lysate, or a growth factor, for manufacturing a drug for the treatment of tissue lesions. Some other embodiments can be used in particular in the veterinary and pharmaceutical fields.

Composition for treating tissue lesions

A process for treating fibroses including administering a therapeutically effective amount of a pharmaceutical composition which includes at least one biocompatible polymer of the following general formula (I): AXYwherein: A represents a monomer selected from the group consisting of a sugar or &#x2014;(O&#x2014;CH&#x2014;CH&#x2014;CO)&#x2014;, X represents a carboxyl group bonded to monomer A, Y represents a sulfate or sulfonate group bonded to monomer A a represents the number of monomers A such that the mass of the polymers of formula (I) is greater than approximately 5,000 da, x represents a substitution rate of the monomers A by the groups X, which is between approximately 20 and 150%, and y represents a substitution rate of the monomers A by the groups Y, which is between approximately 30 and 150%.

Biocompatible polymers, process for their preparation and compositions containing them

The invention relates to a biocompatible polymer having general formula (I) AaXxYy, wherein: A denotes a monomer; X denotes an RCOOR' group; Y denotes an O or N-sulphonate group which is fixed to A and which has either formula &#x2014;ROS03R&#x2032; or &#x2014;RNS03R&#x2032; in which R denotes an optionally branched and/or unsaturated aliphatic hydrocarbon chain which can contain one or more aromatic rings and R&#x2032; denotes a hydrogen atom or a cation; a denotes the number of monomers; x denotes the rate of substitution of the A monomers by the X groups; and y denotes the rate of substitution of the A monomers by the Y groups. More specifically, the invention relates to the use of said biocompatible polymers for the preparation of a pharmaceutical, dermatological or cosmetic composition or a medical device, which are intended to prevent, relieve and/or treat discomfort, distress, itches, irritations and/or pain and/or to protect tissues against same. In addition, in certain cases, the use of said biocompatible polymers for pain treatment can impact on the actual curing of certain diseases. Significant improvements and even cures have been observed in relation to chronic and painful diseases that are associated with alterations in the extracellular matrix regardless of the origin thereof.

Use of biocompatible polymers for the preparation of a composition or a medical device

A process for treating fibroses including administering a therapeutically effective amount of a pharmaceutical composition which includes at least one biocompatible polymer of the following general formula (I): AXYwherein: A represents a monomer selected from the group consisting of a sugar or &#x2014;(O&#x2014;CH&#x2014;CH&#x2014;CO)&#x2014;, X represents a carboxyl group bonded to monomer A and is contained within a group according to the following formula: &#x2014;R&#x2014;COO&#x2014;R', in which R is a bond or an aliphatic hydrocarbon chain, optionally branched and/or unsaturated, and which can contain one or more aromatic rings except for benzylamine and benzylamine sulfonate, and R&#x2032; represents a hydrogen atom or a cation, Y represents a sulfate or sulfonate group bonded to monomer A and is contained within a group according to one of the following formulas: &#x2014;R&#x2014;O&#x2014;SO&#x2014;R&#x2032;, &#x2014;R&#x2014;N&#x2014;SO&#x2014;R&#x2032;, &#x2014;R&#x2014;SO&#x2014;R&#x2032;, in which R is a bond or an aliphatic hydrocarbon chain, optionally branched and/or unsaturated, and which can contain one or more aromatic rings except for benzylamine and benzylamine sulfonate, and R&#x2032; represents a hydrogen atom or a cation, a represents the number of monomers A such that the mass of the polymers of formula (I) is greater than approximately 5,000 da, x represents a substitution rate of the monomers A by the groups X, which is between approximately 20 and 150%, and y represents a substitution rate of the monomers A by the groups Y, which is between approximately 30 and 150%.

A biocompatible polymer constituted by a sequence of identical or different components of the general formula (I): AXY, in which A represents a monomer, X represents a carboxyl group fixed on a monomer A, Y represents a sulfate or sulfonate group fixed on a monomer A; a represents the number of monomers A, x represents the substitution rate of the set of monomers A by the groups X, y represents the substitution rate of the set of monomers A by the groups Y. The invention also pertains to the pharmaceutical or diagnostic compositions containing at least one polymer of general formula (I).

Process for treating fibroses with biocompatible polymer

The invention concerns peptide fragments 13-39 and 65-97 of the HARP factor, which inhibit angiogenesis. Advantageously, said peptides can be associated with the peptide 111-136 of HARP. The invention also concerns pharmaceutical compositions comprising said peptides or nucleic acids encoding said peptides, and their use for treating pathologies associated with an angiogenesis, in particular proliferative disorders such as cancer.

Peptide fragments of the harp factor inhibiting angiogenesis

A pharmaceutical composition for stimulating production of cytokines of inflammation including a peptide corresponding to formula (I) below:(A)-A1-A1-A2-A1-A3-A4-A1-(A)in which A is any amino acid, n and m are each whole numbers from 0 to 20 whose sum n+m is between 0 and 20, A1 is a basic amino acid and more particularly lysine (Lys) or arginine (Arg), A2 is an amino acid selected from the group consisting of basic amino acids, glutamic acid (Glu), glycine (Gly) and aspartic acid (Asp), A3 is an amino acid selected from the group consisting of basic amino acids, proline (Pro), glutamic acid (Glu) and glutamine (Gln), A4 is an amino acid selected from the group consisting of basic amino acids, glutamic acid (Glu), glycine (Gly), serine (Ser) and valine (Val), and a pharmaceutically acceptable carrier.

Peptides which stimulate the expression of the cytokines of inflammation and promote tissue regeneration

A biocompatible polymer constituted by a sequence of identical or different components of the general formula (I): A X Y , in which A represents a monomer, X represents a carboxyl group fixed on a monomer A, Y represents a sulfate or sulfonate group fixed on a monomer A; a represents the number of monomers A, x represents the substitution rate of the set of monomers A by the groups X, y represents the substitution rate of the set of monomers A by the groups Y. The invention also pertains to the pharmaceutical or diagnostic compositions containing at least one polymer of general formula (I).

Use of at least one polymer or one biopolymer called HBGFPP, specifically protecting the growth factors of FGFs and beta TGFs families from tryptic degradation in the manufacture of a drug for the treatment of lesions of the nervous system.

Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate

HARP family growth factors

Drug and pharmaceutical composition for the treatment of lesions of the

Drug and pharmaceutical composition for the treatment of muscles

Compositions useful for regenerating cells and tissues comprise at least one functionalized dextran which has been substituted with carboxymethyl, benzylamide, or benzylamide sulfonate. These dextrans can be used alone or in combination with acid or basic fibroblast growth factors to enhance tissue or cell regeneration. Additionally, these dextrans enhance the stability of acid or basic fibroblast growth factors.

Method of regenerating cells and tissues using functionalized dextrans

The present invention relates to the application, as the stationary phase in affinity chromatography for the purification of the FGF type growth factors, of the polymers or copolymers onto which --SO.sub.3 H and --SO.sub.3 M groups are randomly bound, groups in which M denotes a physiologically acceptable metal, as well as, preferably, --SO.sub.2 R groups, in which R denotes a radical obtained by removal of a hydrogen atom from the amino group of an amino acid or an amino acid derivative. The invention relates also to the obtaining of a purified bFGF or aFGF growth factor, or a mixture of these growth factors, consisting in carrying out an affinity chromatography on a resin such as defined hereinabove, by carrying out an elution with a neutral pH buffer having an ionic strength equivalent to that of a 0.15 M to 2.5 M NaCl solution.

Application of resins consisting of functional polymers as the

A process for stimulating the growth of epidermis cells. The epidermis cells are contacted with an aqueous saline extract (RE) of ocular tissues. The process is especially applied for human epidermis cells. Application to the study of chromosomes of the human epidermis cell, particularly for the detection of natural or induced chromosome anomalies, and to the production of grafts, and especially autografts, usable on man, for example in the treatment of burns, cosmetic and diagnostic products.

Growing community of inventors

Paris, France

Denis S Barritault